Caught in a Covid-19 maelstrom, Eli Lilly locks down clinical trials as multibillion-dollar R&D ops derail
The Covid-19 pandemic has derailed Eli Lilly’s $6 billion R&D operations.
The pharma giant reported Monday morning that it has …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.